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Preamble
The American Institute of Ultrasound in Medicine
(AIUM) is a recognized authority in the clinical utility,
education, and safety of ultrasound imaging. The AIUM
has many standing committees, including the Clinical
Standards Committee, Continuing Medical Education
Committee, and Ultrasound Practice Accreditation
Council. The Bioeffects Committee monitors the safety of
ultrasound and contrast agents on a continuing basis.1,2
As a multispecialty, clinically oriented organization of
ultrasound specialists, the AIUM participates closely in
developments that it identifies as essential for the medi-
cal community to improve patient care. The introduction
of ultrasound contrast media in the mid-1990s has
already revolutionized the practice of ultrasound imaging
in those countries where they are available. In particular,
it has been established that ultrasound imaging per-
formed with contrast enhancement (contrast-enhanced
ultrasound [CEUS]) allows for accurate characterization
and detection of focal liver lesions, which often are
not possible with conventional ultrasound imaging.
Numerous single- and multi-center investigations of
CEUS have shown that both detection and characteriza-
tion of liver masses are comparable to those achieved
with contrast-enhanced computed tomographic (CT) or
magnetic resonance (MR) scans. Ultrasound imaging
performed with contrast enhancement is clearly superior
to ultrasound imaging performed alone. In fact, the lack
of specificity for the confident diagnosis of liver masses
with ultrasound imaging alone is so well recognized that,
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in most cases, the identification of a liver mass on
ultrasound imaging provokes confirmatory imag-
ing with either a CT or an MR scan. In patients at
risk for hepatocellular carcinoma or metastases,
there is recognition that confirmation of all
masses identified on ultrasound imaging with
either CT or MR scans is essential.
In addition to the lack of specificity for ultra-
sound-based diagnosis of liver masses, ultra-
sound-based detection of focal liver masses can
be poor, especially in patients at risk for
metastatic liver disease. Although some metas-
tases may be easily seen on ultrasound imaging
because they are either echogenic or hypoechoic
relative to the liver parenchyma, many others
have backscatter similar to that of the back-
ground liver. These so-called “isoechoic” or
“invisible masses” have backscatter that is iden-
tical to that of the adjacent normal parenchyma,
and they are difficult if not impossible to detect
without the aid of ultrasound contrast. Studies
have shown that these masses can be identified
with a sensitivity comparable to that of contrast-
enhanced CT or MR imaging by the addition of
ultrasound contrast agents. A review of the world
literature on the efficacy of CEUS imaging com-
pared with non-CEUS imaging for the detection
and characterization of liver lesions is docu-
mented in “Appendix A.”
A key element in the evolution of medical imag-
ing technology has been the development from
plain imaging to techniques enhanced by
intravascular contrast agents. In many countries
outside the United States, it is no longer consid-
ered sufficient to perform only non-CEUS imag-
ing of the liver for detection and characterization
of focal liver masses.
It is the AIUM’s considered opinion that the lack
of availability of CEUS for noncardiac imaging in
the United States hinders the delivery of optimal
diagnostic imaging services to our patients. As a
result, we lag behind the rest of the world in the
appropriate and proven uses of contrast agents
for liver mass diagnosis and detection. The AIUM
believes that this is having an adverse impact on
clinical care in the United States.
Therefore, pursuant to the request by the US
Food and Drug Administration (FDA), the AIUM
proposes the following recommendations for
consideration for future CEUS clinical trials.
I. Appropriate End Points for Assessment
of Ultrasound Contrast Efficacy in the
Liver
Ultrasound imaging of the liver in the United
States is currently performed without contrast
media. Contrast media are intended to improve
lesion conspicuity for increased lesion detection
sensitivity and/or to improve lesion characteriza-
tion for increased diagnostic specificity. Improved
detection sensitivity and/or diagnostic specificity
when a contrast agent is used compared with con-
ventional non-CEUS imaging should be sufficient
to establish efficacy for approval. A recommended
trial, therefore, should compare the non-CEUS
imaging performance with the CEUS imaging per-
formance against an accepted truth standard. The
basis for FDA approval should be a significant
improvement of CEUS over non-CEUS imaging.
The AIUM believes that there are situations in
which it is clearly obvious that the improved
diagnostic/prognostic information achieved
with CEUS imaging is clinically useful. These
should be considered an adequate basis for FDA
approval. Possible beneficial outcomes from the
use of CEUS may include, but are not limited to,
the following:
• Improved characterization of focal liver
masses with CEUS imaging, such as to
determine whether a focal liver mass is
benign or malignant, compared with non-
CEUS imaging.
• Improved ability to detect focal liver masses
with CEUS imaging.
• A reduction in referral for further workup
using other imaging or diagnostic procedures.
• Assessment of therapeutic response.
II. Examination Procedures
A. The contrast agent should be prepared
and administered according to the manu-
facturer’s recommendations.
B. Equipment should be quality controlled
and capable of performing CEUS imaging
as described in section III, “Equipment
Criteria and Variables.”
C. Scans should be performed by qualified
personnel as described in section V,
“Training.”
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D. Baseline (noncontrast) ultrasound imag-
ing should include representative images
of the liver and any visible hepatic lesions.
E. Contrast-enhanced ultrasound image
data should be acquired and stored as a
real-time digital data set from before con-
trast agent injection until achievement of
the diagnostic effect as determined for
each agent/protocol.
III. Equipment Criteria and Variables
A. Contrast studies of the liver require con-
trast-specific imaging modes that operate
at a low mechanical index (MI).
B. The trial protocol should specify the per-
formance requirements of high-end sys-
tems for the study.
C. Manufacturers of ultrasound equipment
have products with specifically designed
presets for CEUS imaging of the liver, and
these should be used.
D. Machine presets should include system
parameters as well as settings that can be
controlled by the user. Careful limits
should be placed on the ability of the user
to adjust controls once the preset has
been selected. Considerations for specific
settings should include the following:
1. Nonlinear Contrast Imaging Mode. As
real-time imaging is a key requirement
for liver imaging, a low-MI mode is
needed that does not disrupt the con-
trast microbubbles. The mode detects
the echo returning from the bubbles
and suppresses the echoes from the
tissue containing them. Nonlinear
modes that meet these requirements
usually employ multiple pulses, which
are modulated in phase and/or ampli-
tude. These schemes go under various
commercial names. A machine that
does not offer such a mode is not suit-
able for contrast imaging. Examples of
suitable modes in some systems cur-
rently on the market are listed in
“Appendix B.”
2. Available Transducers. The appropriate
transducer for contrast imaging of the
liver must be specified in the protocol.
3. Mechanical Index. The MI should be
maintained at a level that minimizes
microbubble loss in the anatomic
region of interest. The actual exposure
of the agent to the ultrasound beam
varies with anatomic conditions, so
the fixed setting of MI provided by the
preset should be used as a starting
point. The displayed MI is an estimate
only; actual microbubble loss is deter-
mined by factors other than the MI
alone. Therefore, the appropriate MI
setting should be determined sepa-
rately for each ultrasound scanner
model and the body habitus of each
specific patient. In general, the lowest
MI consistent with a successful exam-
ination should be used.
4. Operating Frequency. The operating
frequency for a given machine should
be specified in the protocol. In general,
contrast-specific nonlinear imaging
modes are more sensitive at lower
operating frequencies, which also offer
better penetration but lower spatial
resolution. Thus, sensitivity to the
agent is added to the trade-off between
resolution and penetration.
5. Multiple Modes. The user must be able
to view both the noncontrast and con-
trast images because contrast-specific
imaging modes suppress the echo
from tissue. Machines that offer
simultaneous noncontrast and con-
trast-specific images are preferred.
The noncontrast image MI should be
controlled so that no inadvertent
microbubble loss occurs.
6. Line Density/Frame Rate. In general,
the lower the exposure of microbub-
bles to ultrasound, the lower the rate of
microbubble loss. Reducing line densi-
ty and frame rate to the minimum con-
sistent with diagnostic interpretation
is recommended. Zoom or magnifica-
tion modes should not be used. 
7. Focal Zones. Focal zone settings
should be set according to manufac-
turers’ instructions and not changed
during an examination.
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8. Initial Gain. The initial gain setting, if
not provided automatically by the
machine, should show system noise in
the far field of the contrast image. 
9. Data Storage. The machine should be
capable of capturing real-time image
data, preferably continuously, for the
duration of the contrast enhancement
(at least 3 minutes is required). Storage
to a local or network device is required.
E. Trial designers should work with system
manufacturers to standardize machine
presets for each trial.
F. Contrast-enhanced ultrasound modes
should be well documented, with setup
algorithms and work flow guides (see
“Appendix B”). A step-by-step procedure
for use of the system during the examina-
tion should be specified.
G. While the technology for CEUS modes
may continue to evolve, it is recommend-
ed that the technology for an individual
trial should not be changed once the trial
begins.
IV. Safety
In medical procedures, considerations should
always be given to comparing the risks with the
benefits to the patient. Clinical utility from
improved diagnostic image information has
been demonstrated with ultrasound contrast
agents. Approval for the use of such agents in the
United States and internationally has resulted in
numerous examinations using a variety of agents
(millions of doses). The general safety record of
ultrasound contrast agents has been quite good,
as discussed below. It is the responsibility of the
ultrasound community to help maintain the
safety record of ultrasound imaging and deter-
mine any risks associated with the methods
used. Several aspects need to be considered:
General Safety Record of Ultrasound Imaging
Medical ultrasound imaging has been used since
the 1950s. Since its introduction, this modality
has been considered one of the safest methods of
medical imaging. As indicated by the general
clinical safety statement from the AIUM (see
“Clinical Safety” at http://www.aium.org/
publications/statements/statements.asp), there
are no confirmed harmful biological effects in
patients from exposure to ultrasound energy at
levels commonly used for diagnostic imaging.
The possibility exists that biological effects may
be identified in the future, but the benefits of the
prudent use of ultrasound outweigh the risk, if
any, that may be present. Although this state-
ment has largely been considered in terms of
conventional non-CEUS imaging, it is important
to remember that the same assessment should
be made when weighing benefits and risks in
clinical CEUS imaging. In the absence of specific
evidence of risk and with demonstrated patient
benefit, the prudent use of contrast agents
should be appropriate. Additionally, when the
use of a contrast agent provides significant diag-
nostic information, not performing such a pro-
cedure may also increase medical risk to the
patient.
Potential for Bioeffects
The currently approved ultrasound contrast
agents use microbubbles to produce the added
contrast provided by the agent. Contrast agents
are a relatively new addition to ultrasound imag-
ing, and identifying potential risks is an ongoing
process. There is a wealth of theoretical and
experimental knowledge about the interactions
of microbubbles and ultrasound energy. This
knowledge results from a considerable number
of investigations on bubble-ultrasound interac-
tions, including cavitation activity that can have
enough energy to induce bioeffects.
There have been several studies in vitro and in
animal models that have shown potential bioef-
fects. Many of these animal studies have been
related to ultrasound exposure of cardiac tissue
in the presence of microbubble contrast
agents.3–10 One early study in humans reported
induction of premature ventricular contrac-
tions (PVCs) using a high MI and end-systolic
triggering.11 However, other studies using differ-
ent exposure conditions did not find an
increased frequency of PVCs.12–15 The induction
of PVCs in humans appears to require a relative-
ly high MI, imaging at a specific point in the car-
diac cycle, and substantial contrast agent filling
of the cardiac tissue.
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In terms of noncardiac studies, some animal
studies have been positive for effects,7,16–19 but
the relationship to the clinical situation has not
been clearly established. Of particular relevance
to cancer imaging, 1 study20 did not find an
enhancement of metastatic spread in mouse
melanoma tumors using diagnostic levels of
ultrasound in the presence of contrast agents.
The identification of any potential biological
effect must be placed in context. The likelihood
of the effect in the clinical situation and the clin-
ical significance of such effects should be
assessed.
To the credit of the ultrasound community,
there have been very active researchers who
have carefully considered mechanisms for bio-
logical effects of ultrasound. These individual
researchers and collective activities such as those
of the Bioeffects Committee of the AIUM have
helped identify potential effects that have been
explored further. These efforts should continue
as part of maintaining the established reputation
of diagnostic ultrasound as safely practiced in
medicine. The prudent use of ultrasound and
CEUS imaging, including the application of the
ALARA (as low as reasonably achievable) princi-
ple, should continue to the benefit of patients.
Safety of CEUS Imaging
It has been recognized for years that there are
finite risks associated with the use of contrast
media in medical imaging. For example, the
adverse reaction rates of intravenous CT contrast
agents are 4% to 12% for ionic contrast and 1% to
3% for nonionic.21 For ultrasound contrast
agents, the most common effects are headache,
a warm sensation, and flushing, all of which
resolve in a short time. More unusual events
such as nausea, dizziness, chills, altered taste,
and chest pain occur in 0% to 5% of patients at a
rate similar to that seen in placebo groups.22
Note that in postmarketing surveillance, the
serious adverse event rate for gadolinium
diethylenetriaminepentaacetic acid in MR imag-
ing was found to be 1 to 2 per 100,000.23
Considering the most extreme effects, the death
rate from intravenous CT contrast agents is 1 to 3
per 100,000 (0.002%).21 Only 3 deaths in approxi-
mately 160,000 doses were reported in conjunc-
tion with current ultrasound contrast agent use,
all associated with 1 agent. However, continued
use of this agent with changes in contraindica-
tions has yielded no additional fatalities, and
debate remains as to the role of the agent in the
previous deaths. No deaths have been attributed
to the other agents in clinical use in the United
States and elsewhere. The total number of doses
for all ultrasound contrast agents combined is
now almost 2 million. Therefore, the death rate
associated with ultrasound contrast agents is
likely significantly less than that from CT con-
trast agents.
Obviously these are investigations of common-
ly found adverse effects, and further study would
be needed to follow any potential adverse effects
unique to ultrasound contrast agents. However,
the general safety profile is as good as or better
than that of other imaging agents that are rou-
tinely used and currently deemed as acceptable
risks given the benefits to the patient.
Guidance for Clinical Trials
As with any ultrasound procedure, the ALARA
principle should be followed; that is, one should
use only the ultrasound output power level and
contrast agent dose needed for diagnostic effica-
cy. In terms of ultrasound exposure, the advent of
low-MI imaging has significantly reduced the
requisite pulse amplitude for optimal contrast
imaging. Information from bioeffects studies in
animals has generally found a threshold for
effects at an MI of approximately 0.4, generally
higher than those typically used for low-MI
imaging. This might serve as some guidance in
CEUS imaging studies; however, again the spe-
cific need for higher output levels to achieve
diagnostic information may be justified. For
example, higher levels of acoustic power may be
required on the basis of patient factors such as
obesity or a deeply located lesion or if the con-
trast is to be eliminated from the imaging field to
measure contrast flow dynamics into a lesion. In
any case, the lowest level of acoustic output nec-
essary has always been a guiding principle in
medical ultrasound, and this is unchanged when
considering the use of CEUS imaging.
The lack of availability of CEUS imaging for
noncardiac applications in the United States
denies patients a beneficial procedure, resulting
in other forms of risk.
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V. Training
The AIUM recognizes the importance of proper
qualifications of investigators and blinded read-
ers who participate in clinical trials of CEUS.
Proper experience and training are important
for ultrasound imaging professionals to partici-
pate in clinical trials using ultrasound contrast
agents. Although the use of contrast media
requires unique skills that may not be possessed
by many professionals in the United States,
these skills are not difficult to learn provided the
professionals have a minimum level of knowl-
edge and experience in clinical ultrasound
applications. Participation in such a program is
intended to ensure a standard skill set for the
purposes of the clinical trial and is not necessary
after contrast agent approval, although appropri-
ate training should be obtained by those per-
forming clinical CEUS.
Training cases are recommended before
enrolling subjects. In addition, qualified study
personnel familiar with both imaging technology
and contrast agent procedures should serve as
onsite monitors to ensure the quality of patient
examinations. Two training program models are
shown in “Appendix C.”
VI. Conclusion
The AIUM believes that implementation of these
recommendations will decrease variance among
sites and increase the likelihood of successful
clinical trials.
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Appendix B: Work Flow Examples
The following manufacturers have provided current examples of work flow sequences for the use of
CEUS: GE Healthcare (Milwaukee, WI), Philips Medical Systems (Bothell, WA), and Siemens Medical
Solutions (Mountain View, CA). Work flow sequences from other manufacturers will be added as they
become available. Draft summaries are below.
1. Contrast Work Flow for Coded Contrast Imaging, GE LOGIQ 9, 7, and 5 (Draft)
Select New Patient control on console Enter patient information; select Abdominal preset; exit
Select transducer System will automatically default to factory- or user-
programmed image parameter settings for a routine exam
Select Contrast control on console Contrast menu appears on touch panel 
Select TruAgent Detection on touch panel System will automatically default to factory- or user-
programmed low-MI contrast-specific image parameter
settings, including: 
• Operating Frequency
• Acoustic Output
• Gain
• Dynamic Range
• Line Density
• Edge Enhance
• Pulse Repetition Integral
• Focal Zone number and position
• Gray Map
• Dual View Imaging mode
Adjust gain and focal zone position as 
necessary
Select Contrast Clock on touch panel on Contrast timer displays on monitor
agent injection
Select  Print 1 on console to store loops System will store raw DICOM image or loop to system
or still images hard drive
Select End Exam on exam completion System displays all recorded images and loops, ends exam,
and resets for next patient entry
(continued)
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Appendix B (continued): Work Flow Examples
2. Contrast Work Flow for Philips iU22 (Draft)
Enter patient demographics Press Patient Data key System provides screen menu for
patient data entry
Cine loop capture length Setups Print/Network tab Set prospective capture length to 
3 minutes (only needs to be set
once)
Select transducer (or select exam Select Contrast Gen preset System sets parameters for low-MI
first) B-mode for preinjection imaging
Invoke contrast mode Press Contrast Touch Panel • System activates low-MI contrast
(TP) button agent imaging
• System sets transmit frequency/
line density across sector
• System sets transmit focus to
encompass depth of field
• System sets acoustic power to 
MI 0.07
• System sets initial gain value
• System sets persistence value
• System sets gray map value
• System sets Xres values
• System sets compression
• System sets 2-dimensional pulse
repetition frequency
Administer agent Press Contrast Timer TP System time stamps each frame in
button system with time since injection
for viewing in review
Record clip Press Capture System simultaneously records
DICOM and native data clips of
up to 3 minutes
Stop recording clip Press Capture key System stops clip store
Terminate time stamp Press Contrast Timer System stops rolling timer
To change transmit frequency Toggle 2D Opt (Pen, Gen, System sets new transmit 
Res) frequency and recalculates MI
and MI at the focus (MIF) values
To display live dual imaging Press Contrast Side/Side System displays agent image on
one side and tissue image on the
other side
To do region of interest (ROI) Press QLab, in review; Select ROI or MVI 
analysis or microvascular then press ROI or MVI
imaging (MVI) processing 
(to view bubble outline of 
vasculature)
(continued)
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Appendix B (continued): Work Flow Examples
3. Contrast Work Flow for Contrast Pulse Sequencing (CPS), Siemens Sequoia System
Enter patient demographics Press Begin Exam key System provides screen menu for
patient data entry
Select exam (or select Press Exam key; select CPS
transducer first) Abdomen from Exam list
Select transducer (or select Press Transducer key; select • System sets parameters for standard
exam first) transducer from soft key B-mode preinjection imaging
• System sets standard B-mode
imaging presets
• Exception: system sets digital
clip capture for 8 minutes
Invoke contrast mode Press Cadence key • System activates low-MI CPS
agent imaging
• System sets to lowest transmit
frequency
• System sets transmit focus to
encompass depth of field
• System sets acoustic power to
–21 dB and calculates corre-
sponding MI and MIF
• System sets initial gain value
• System sets persistence value
• System sets post processing 
map value
• System sets enhancement value
• System sets Delta value
• System sets agent-only display
Equalize image brightness Press TEQ key • System sets lateral and axial gain
• System detects and subtracts
background noise
Administer agent Press Stopwatch key System time stamps current time of day
and initiates rolling stopwatch
Record clip Press Clip Store key System simultaneously records
DICOM and QuickTime clips of
up to 8 minutes
Stop recording clip Press Clip Store key System stops clip store
Terminate time stamp Press Stopwatch Stop/Reset System stops rolling stopwatch
soft key and zeros stopwatch
To change transmit frequency Toggle MultiHz key System sets new transmit frequency
and recalculates MI and MIF values
To display live dual imaging Press Dual key System displays agent image on one
side and tissue image on the other side
To switch from agent-only to Toggle Balance key System displays mixed agent and
mix or tissue-only display tissue image or tissue-only image
or agent-only image
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Appendix C: A CEUS Imaging Training Program 
Two concepts for training programs have been developed as described in the outline below. 
The training programs are generic (ie, they are not designed to be used for a specific contrast prod-
uct), but they could be easily modified to incorporate any unique or product-specific requirements
related to a given ultrasound contrast agent (eg, preparation, doses, etc). Once the trainees complete
the training program(s), they would be required to take an examination that would indicate their
level of competency in CEUS imaging studies.
Participants
Proof of adequate experience and/or participation in these training programs is required for all ultra-
sound imaging professionals that intend to perform CEUS examinations as part of clinical trials and
those that will function as “blinded readers” of CEUS studies performed in other laboratories.
It is suggested that proof of adequate experience and/or participation in a training program also be
required for clinical representatives (eg, application specialists, etc) of pharmaceutical and ultrasound
system vendors that will be involved in the clinical trials.
Similar training programs could be used for professionals that desire CEUS training after CEUS is
approved for clinical trials.
Training Programs
I. Two training programs could be developed.
A. One program would be designed for physicians who intend to be “blinded readers” for CEUS
clinical trials.
B. One program would be designed for physicians and sonographers who intend to participate in
CEUS clinical trials.
II. Applicants would be required to possess prerequisite qualifications to participate.
A. For physicians, board certification and a minimum of 5 years’ experience in ultrasound would
be required.
B. For sonographers, American Registry for Diagnostic Medical Sonography certification in abdom-
inal ultrasound would be required.
C. Laboratory accreditation as a requirement may be considered.
D. Qualified individuals could participate in either or both training programs. 
III.Training programs would be generic in terms of the contrast media (ie, they would not be designed
for a specific contrast product). 
IV. Applicants would be required to take a pretest before beginning the training programs and a
posttest after completion of the programs.
A. Use of pretests and posttests permits analyses of the level of knowledge that trainees obtain by
completing the training programs as well as the adequacy of the educational programs.
V. Relevant reference materials would be made available to applicants.
A. Materials may include published reports, book chapters, European contrast agent guidelines,
white papers, etc.
VI. Training would include the following:
A. Didactic training for all applicants. 
B. Hands-on training for applicants who intend to perform CEUS clinical trials.
C. Didactic lectures would include the following:
1. Physical principles of CEUS, including instrumentation and scanning techniques.
(continued)
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Appendix C (continued): A CEUS Imaging Training Program 
2. A review of the relevant anatomy, physiology, and pathology as it pertains to CEUS for liver
applications.
3. Pitfalls, limitations, safety, and other relevant issues.
4. Patient/subject selection.
D. Hands-on training would use a wet lab with an animal model and all ultrasound systems that
are deemed appropriate for CEUS trials.
1. Trainees would perform CEUS studies using equipment that they would use in their own lab
with supervision by CEUS-experienced nurses, sonographers, and physicians.
2. Contrast media manufacturers’ representatives would also be involved in the wet lab training
(for a given agent).
VII. Case reviews would be performed.
A. Before the trainees could perform or interpret CEUS protocol studies, a specified number of
CEUS teaching cases would be reviewed.
1. The training cases would be in real time on DVD (or other video format). 
2. Trainees would review the cases and complete a questionnaire that would include a descrip-
tion of the features of the CEUS studies, diagnostic impressions/differentials, limitations, level
of suspicion, final assessment, etc. 
3. The trainees’ responses on the forms would be compared with those of a panel of experts.
VIII. Trainees who successfully complete the formal training programs, case reviews, and post- 
tests would be “signed off” as being competent to perform and/or interpret CEUS protocol
examinations.
A. Trainees who do not successfully complete either the formal training and/or the required num-
ber of case reviews would be required to continue the training process with emphasis on their
areas of weakness as determined by the posttest and/or case review questionnaires. They would
then be required to retake the posttest until successful.
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